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Abstract: Accurate phenotyping of patients with pulmonary hypertension (PH) is an integral part
of informing disease classification, treatment, and prognosis. The impact of lung disease on PH
outcomes and response to treatment remains a challenging area with limited progress. Imaging
with computed tomography (CT) plays an important role in patients with suspected PH when
assessing for parenchymal lung disease, however, current assessments are limited by their semi-
qualitative nature. Quantitative chest-CT (QCT) allows numerical quantification of lung parenchymal
disease beyond subjective visual assessment. This has facilitated advances in radiological assessment
and clinical correlation of a range of lung diseases including emphysema, interstitial lung disease,
and coronavirus disease 2019 (COVID-19). Artificial Intelligence approaches have the potential to
facilitate rapid quantitative assessments. Benefits of cross-sectional imaging include ease and speed
of scan acquisition, repeatability and the potential for novel insights beyond visual assessment alone.
Potential clinical benefits include improved phenotyping and prediction of treatment response and
survival. Artificial intelligence approaches also have the potential to aid more focused study of
pulmonary arterial hypertension (PAH) therapies by identifying more homogeneous subgroups of
patients with lung disease. This state-of-the-art review summarizes recent QCT developments and
potential applications in patients with PH with a focus on lung disease.
Keywords: pulmonary hypertension; PH-Lung disease; quantitative CT; hypoxia; artificial intelli-
gence; machine learning; pulmonary arterial hypertension
1. Introduction
Pulmonary hypertension (PH) is a heterogeneous, life-limiting condition defined
by an elevated pulmonary artery pressure and, if untreated, results in right ventricular
failure and death. The current classification of PH identifies five groups, each with shared
pathophysiological characteristics [1]. However, increasingly, patients are identified with
overlapping features. Group 3 PH—pulmonary hypertension in association with lung
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disease and/or hypoxia (PH-Lung)—is a complex, highly heterogeneous group where pre-
capillary PH most commonly complicates chronic obstructive pulmonary disease (COPD)
and/or emphysema, interstitial lung disease (ILD), and alveolar hypoventilation [2–5].
These conditions may also co-exist to varying degrees, and patients with a combination
of pulmonary fibrosis and emphysema (CPFE) with severe PH have a particularly poor
prognosis [3]. Usually, patients with PH in association with lung disease have a mild
elevation of pulmonary artery pressure in keeping with the severity of the underlying
lung disease, however, some patients present with severe PH with variable degrees of
parenchymal involvement [5]. A review by Kovacs et al. highlighted the spectrum of
pulmonary vascular involvement in patients with COPD [6]. In these patients, it is impor-
tant to exclude other forms of PH, such as Group 1 PH, pulmonary arterial hypertension
(PAH), and group 4 PH (chronic thromboembolic pulmonary hypertension (CTEPH)) [7].
Idiopathic pulmonary arterial hypertension (IPAH) is a form of PAH where no other cause
of PH is identified, although, in some cases, it has a heritable component [8–10]. Current
guidelines recommend that patients with severe pre-capillary PH with no other cause
identified be classified as Group 1 IPAH [5,11], whereas patients with severe lung disease
and mild PH are classified as having Group 3 PH-Lung. However, in clinical practice, some
patients do not neatly fit into either category, and this creates a clinical dilemma (Figure 1).
The recommended managements of IPAH and PH-Lung are divergent. The last
decade has seen the introduction of multiple novel PAH specific drug therapies targeting
endothelin, nitric oxide, and prostanoid pathways [12]. These have improved the outlook
for PAH, particularly in younger patients with IPAH where the UK National Audit reports
a 5 year survival in excess of 80% [13]. Previous data from the ASPIRE ) Assessing the
Spectrum of Pulmonary Hypertension Identified at a Referral Centre) Registry highlighted
the impact of lung disease on survival compared with other forms of PH. Patients with
PH-Lung assessed at a PH referral center had a 5 year survival of 31%, worse than all
other forms of PH [14]. For patients with severe PH-Lung, the survival is particularly
poor, worse in ILD compared to COPD [14]. In contrast to Group 1 PAH, for patients with
Group 3 PH-Lung, guidelines recommend treatment of the underlying lung disease or, in
highly selected cases, lung transplantation. Interestingly, the sixth World Symposium on
PH (WSPH) recommended that patients with minor lung disease, who otherwise meet the
criteria for PAH with no other causes identified, should be considered to have IPAH [5].
This recommendation was based on unpublished subgroup analysis in patients with mild
to moderate lung disease from randomized controlled studies [15–17]. However, a recent
publication demonstrated that patients diagnosed as IPAH using criteria from the sixth
WSPH with mild lung disease had significantly worse survival with no improvement in
exercise capacity or quality of life [11]. This study highlights the challenge of classifying
patients with PH and a need for improved disease phenotyping to ensure that the most
appropriate patients receive treatment and, where uncertainty exists, that patients are
entered into appropriate clinical trials.
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Figure 1. Spectrum of lung disease severity within pulmonary hypertension and the diagnostic and
treatment dilemma. Five year survival figures quoted from REVEAL (Registry to Evaluate Early and
Long-Term PAH Disease Management) registry five year outcomes and recent studies [3,18,19].
Traditionally, the severity of lung disease is quantified using lung function tests using
spirometric values, lung volumes, and measurements of gas diffusion (DLco and Kco),
with increasing evidence showing that DLco is strongly prognostic in a number of forms of
PH [20–22]. Indeed, DLco is part of a widely used risk score, REVEAL (Registry to Evaluate
Early and Long-Term PAH Disease Management) 2.0 [23]. Lung function tests, however,
show significant variability, low reproducibility, and can be insensitive to change to disease
progression [24–26]. Computed tomography (CT) is the gold standard for evaluating
the extent and the distribution of lung parenchymal disease and provides an additional
non-invasive assessment of vascular, cardiac, and mediastinal structures [27,28]. CT is,
therefore, recommended by both the latest joint European Respiratory Society/European
Society of Cardiology PH guidelines and the Pulmonary Vascular Research Institute (PVRI)
statement on imaging in pulmonary hypertension as an important part of the diagnostic
strategy in suspected PH [1,29]. The features and the patterns of disease in PAH and
PH-Lung on CT are visualized in Figures 2 and 3, respectively.
Artificial intelligence (AI) has seen a rise in prominence and performance, especially
with recent machine learning (ML) approaches. It has been labeled as “a major paradigm
shift” and “one of the most fundamental changes in medical care” [30,31]. Within chest CT
and respiratory medicine, there has been an explosion in AI research, with a 5× increase
in studies between 2014–2019 compared to 2010–2014. Correspondingly, there are now
>75 Food and Drug Administration (FDA) and several CE approved AI software packages
in chest CT alone compared to just one in 2014 [32]. We reviewed the literature and found
no studies directly involving AI, chest CT, and PH. There are, however, many studies
involving AI, ML, and chest CT in other diffuse lung diseases such as emphysema, COPD,
ILD, and, recently, COVID-19. Discoveries, solutions, and findings of these studies are
directly applicable to development of AI models in PH.
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Figure 2. Computed tomography (CT) features of pulmonary arterial hypertension (PAH) on CT.
(A) Dilated main pulmonary artery. (B) Right atrial and ventricular dilation with moderate right
ventricular hypertrophy and flattening of the interventricular septum. (C) Centrilobular ground glass
nodularity. These are a feature of PAH but are also more commonly seen in another sub-phenotypes
of pulmonary hypertension, such as pulmonary vascular obstructive disease (PVOD). In PVOD,
they are often accompanied by interlobular septal thickening and mediastinal lymphadenopathy.
(D) Zoomed in view of regions of centrilobular ground glass nodularity.
Figure 3. Patterns of lung disease in pulmonary hypertension in association with lung disease and/or
hypoxia (PH-Lung) as visualized on CT. (A) Mild emphysema localized predominantly to the upper
lobe. (B) Widespread severe emphysema. (C) Combined emphysema and fibrosis. (D) Interstitial
lung disease.
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Despite a number of studies highlighting the negative impact of PH on survival
in PH-Lung [2,7,33], data are very limited for the use of PAH therapies. Studies have
been performed primarily in COPD and ILD and yielded conflicting results [5]. This
reflects, in part, the small numbers, the study designs, and the heterogeneous nature of
patients enrolled. Despite studies with ambrisentan [34] and riociguat [35] identifying
safety concerns in patients with ILD a recent randomized controlled study, INCREASE
demonstrated an improvement in the 6 minute walk test in patients with ILD [36]. This
has re-invigorated the PH community to explore PAH therapies in PH-Lung. However,
given the heterogenous nature of PH in lung disease, a technique to aid the identification
of more homogeneous subgroups of PH-Lung would be very welcome.
Given the potential of AI approaches to assess lung parenchyma, vessels, and cardiac
chambers, the authors postulate that quantitative CT (QCT) could “come to the rescue” of
investigators wishing to improve the outlook for patients with PH-Lung. By improving
phenotyping, AI approaches could aid the characterization of disease and enrich popu-
lations most likely to benefit from PAH therapies. This state-of-the-art review critically
appraises the recent developments in the adjacent fields of ML in CT imaging and con-
textualizes their potential impact on imaging, diagnosis, classification, and assessment of
prognosis in patients with PH with a focus on lung disease.
2. AI, Machine Learning and Deep Learning
2.1. Definitions
Artificial intelligence (AI) is a general term encompassing computer algorithms capa-
ble of performing tasks requiring human intelligence. Figure 4 summarizes the relationship
between different AI approaches. Historically, AI has been trained with a rules-based ap-
proach, where a programmer explicitly creates a set of conditions upon which the machine
executes actions.
Figure 4. Layers of artificial intelligence approaches applied to medical imaging.
Machine learning (ML) is a subset of AI in which algorithms are trained to solve tasks
through feature learning instead of an explicit rules-based approach. When presented with
a “training” cohort, the algorithm identifies salient features, which are subsequently used
to make predictions. Hence, the “machine” “learns” from the data itself.
Deep learning (DL) is a subset of ML which uses multiple layers to extract features.
Each “layer” provides information to the algorithm. “Convolutional neural networks”
(CNNs) are a subset and one approach to “deep learning”, which is loosely inspired by
neurons in the human brain. Several “nodes” exist within multiple layers, and each “node”
as a data point has a weighting which affects the whole “network”. This approach in
particular is most prevalent in the domain of image recognition and analysis and has
demonstrated superior problem-solving capabilities. While most earlier AI methods have
led to applications with subhuman performance, recent deep learning algorithms are able
to match and even surpass humans in task-specific applications [30,37–41]. Two recent
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examples of AI superiority in medical imaging include measuring wall thickness in hyper-
trophic cardiomyopathy on cardiac magnetic resonance imaging (MRI) and diagnosing
breast cancer in mammography [37,42].
2.2. Supervised vs Unsupervised Learning
Two broad categories of ML methods exist—supervised and unsupervised learning.
Supervised learning requires explicit labeling of the training data with a ground truth, upon
which the machine develops its model and makes predictions. Labeling lung parenchymal
disease patterns as “ground glass change” or “emphysema” is an example of supervised
learning. Performance is tested by how well it predicts these labels in a validation cohort.
Unsupervised learning requires no explicit labeling of the training data; rather, it learns to
cluster/group together, thereby requiring very large datasets [43]. The algorithm makes
its own inferences within the data space to learn its internal structure and uses that make
predictions. Semi-supervised learning is a combination of two methods where a smaller
labeled dataset is combined with a larger unlabeled dataset. The labeled dataset is used to
guide the algorithm before it is used in the unlabeled data. The vast majority of all medical
imaging AI studies use supervised learning and are therefore reliant on accurate labeling.
2.3. General vs. Narrow Intelligence
General intelligence is the ability to apply knowledge across a range of domains. A
radiologist is trained to have “general” intelligence across all modalities and age groups,
from detecting congenital anomalies in fetal ultrasounds to complex neurodegenerative
disease in brain MRIs. Methods and skills learned in one domain are often transferable to
other domains. In contrast, almost all state-of-the-art AI advances are currently limited to
narrow intelligence in a defined domain [30]. The focus of such studies has been to match
and occasionally surpass human radiologist performance in that narrow specific instance.
How “narrow” an algorithm is depends on how it was developed and what datasets were
used; an algorithm trained entirely on ILD could not evaluate emphysema.
Figure 5 outlines the multiple stages within a diagnostic radiology workflow, high-
lighting the potential avenues for AI solutions. This review focuses on the image perception
and reasoning stages, however, each stage is a current active research topic of interest.
Figure 5. Stages within a radiology diagnostic workflow with potential artificial intelligence (AI)
applications at each stage. This review focuses on the image analysis stage, incorporating image
perception and reasoning. Image reproduced with permission from original author Dr. Hugh
Harvey [44].
3. Machine Learning in Chest CT
Within image analysis, machine learning in chest CT broadly has two domains: nodule
detection and radiomics. Multiple AI solutions exist for lung cancer nodule detection and
have shown to have a high level of accuracy, sensitivity, and specificity [45–47]. Labeled
public datasets for model development exist, the largest of which is the Lung Image
Database Consortium Image Collection (LIDC-IDRI) [48]. Radiomics is the broad field of
study which aims to extract information from imaging using computer-aided mathematical
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analysis that is not accessible through traditional visual inspection [49]. Initial use was
predominantly in oncology settings to make predictions on disease course, survival, and
treatment response from tumor features [49,50]. Recently, the field has expanded to non-
oncological settings. In diffuse lung diseases, QCT has been the main application of
ML algorithms.
Quantitative CT (QCT) is the principle of extracting quantitative information from
standardized imaging data. This ranges from simple human hand-drawn manual measure-
ments of anatomical structures such as the trachea or the main pulmonary artery (mPA) to
complex AI driven texture analysis of lung parenchymal disease patterns. It has been used
in a range of diffuse lung diseases [51,52]. State-of-the-art applications of QCT use ML and
DL to provide end-to-end solutions, where the entire CT scan is automatically analyzed
with an output provided. Such approaches require a suite of algorithms, from segmentation
where the lung parenchyma is accurately identified and extracted to quantification and
incorporation into clinical models. A recent example is CORADS-AI, which automatically
quantifies and assigns the CORADS (COVID-19 Reporting and Data System) score for
the extent of lung parenchymal in COVID-19 [53]. Figure 6 demonstrates such a QCT
approach using an adaptive multiple features method with different parenchymal patterns
highlighted [54].
Figure 6. Demonstration of a quantitative CT (QCT) approach (adaptive multiple features method), acquired using PASS
software. Different lung parenchymal disease patterns are identified and highlighted. Blue, emphysema/low attenuation
pattern. Yellow, fibrotic changes. Pink, ground glass change.
4. Promise of Quantitative Chest CT in PH
The current standard for assessment of chest CT is by an expert radiologist. This
approach fundamentally treats scans as pictures for subjective visual assessment. QCT
and AI approaches, in contrast, treat scans as imaging data, which can be processed
and analyzed.
AI models can be categorized by their domain of application and corresponding
endpoints. Figure 7 is a summary diagram which visualizes the promise and the advantages
of QCT in each domain—imaging, diagnosis, and prognostication.
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Figure 7. Summary figure. Domains of AI application with corresponding advantages. Increasing
clinical impact through clinically meaningful endpoints.
4.1. Imaging
4.1.1. Repeatability
Radiological assessment is a subjective process. Reports between radiologists differ
significantly in their style and content, and there exists significant inter-observer variabil-
ity on visual assessment, even between highly experienced radiologists [55–57]. Within
chest CT imaging, reports are often broad and give an overall impression of the disease
process. It is either binary (disease present or absent) or a rough categorical assessment
of a degree of severity (mild, moderate, or severe). Clinically significant differences have
been demonstrated, even in assigning final diagnosis in ILD [58].
QCT, in comparison, provides reproducible data which numerically quantify disease
severity [30,59]. It therefore provides an objective measure which can be integrated into
diagnostic and prognostic models. This principle of repeatability minimizes the inherent
variability from a visual approach to imaging.
4.1.2. Increased Efficiency to Counter Rising Demand
The demand for medical imaging is rising far steeper than the available radiology
workforce [30,60,61]. In 2015, it was estimated that an average radiologist must interpret
an image every 3–4 s in a normal 8 hour workday to meet workload demands [62]. The
demand is particularly steep for complex investigations that require longer to report, such
as chest CT and cardiac MRI. These modalities are routinely used in PH and are integral
to assessment.
AI has been shown to improve productivity, reducing the time needed to review
imaging. Within PAH, routine and repetitive tasks such as measuring pulmonary artery
size or right atrial area could be automated, saving time over hand-drawing regions.
Temporal subtraction is an AI method to highlight interval change between successive
imaging [63,64]. In bone CT scans, this method reduced reading time by 43% and increased
sensitivity by 14.6% [65]. PH patients require regular reassessment with imaging to moni-
tor treatment response, and such techniques could help increase the efficiency of repeat
comparative reporting.
Triaging of scans is another area which has seen significant research [66]. Scans are
first read by the AI model which then categorizes them based on probability of disease.
This would enable more efficient use of resources, with radiologists prioritizing those scans
that are likely to involve the disease, thereby reducing time to report and enabling clinical
decision making.
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4.1.3. Novel Methodologies beyond Visual Assessment
A limitation of all current imaging modalities is the inability to visualize and assess
the distal pulmonary artery vascular—the region of disease in PAH [29]. In PAH, large
pulmonary arteries are known to demonstrate dilation, pruning, and abrupt tapering
or tortuosity [67]. Pulmonary vessel morphology is an example of an approach made
possible only through quantitative AI analysis, as it would be unfeasible visually. The
pulmonary vascular tree is segmented, with features such as lumen size, tortuosity, and
tapering quantified. There exist several 3D vessel lumen segmentation techniques in both
CT and MRI to enable this [68]. A deep learning CNN approach recently demonstrated 94%
accuracy in segmentation of the vascular tree [69]. The findings from clinical applications
of such approaches could have an impact on diagnosis and prognostication.
4.2. Diagnosis
4.2.1. Reducing Time to Diagnosis and Error
A dual reader approach has been shown to reduce error and misses. However, this
is prohibitively time and radiologist resource intensive. AI systems have, therefore, been
suggested as an alternative “second reader” and have shown promise in reducing errors
and improving sensitivity [64].
Quantifying severity with a continuous index rather than a broad visually estimated
category can increase potential to detect more subtle changes [51]. In total, 48% of PH
patients do not receive a diagnosis until one year after experiencing symptoms, and 40%
see four or more health care providers prior to diagnosis [70]. Chest CT is commonly
performed, however, radiologists assessing the lungs do not routinely evaluate for features
of PH, and some characteristic abnormalities of CTEPH may be subtle and require specialist
radiology expertise limited to tertiary centers. AI models that automatically evaluate
studies for signs of PH have the potential to reduce the time to diagnosis.
In emphysema, airway wall thickening visualized on incidental chest CT was shown
to be an independent predictor of COPD exacerbations that led to hospitalization or death
in a large multicenter randomized controlled trial [71]. A similar simple approach can
be applied to PH where QCT could automatically segment, measure, and plot the main
pulmonary artery size against a normative curve. This would provide the reporting
radiologist with additional context to evaluate and consider PH as a potential diagnosis.
4.2.2. Improving Phenotyping and Classification
In COPD, new subtypes and phenotypes have been discovered through ML ap-
proaches [72,73]. These distinct patient subtypes characterized by imaging correlate with
physiological parameters. In ILD, QCT metrics have been shown to correlate well with a
range of clinical function tests such as lung function tests [52,59,74,75].
PH-Lung has multiple different phenotypes with distinct treatment responses [2,3].
A current clinical dilemma in PH is differentiating IPAH with mild lung disease from
PH-Lung; therefore, there is a need to understand more about different phenotypes and
why some patients with variable degrees of parenchymal disease do or do not develop
PH [5,76]. New phenotypes have also been proposed in IPAH based on patterns of lung
involvement on CT [6,11] that differ significantly in treatment response to PAH therapy and
prognosis. Quantitative approaches could therefore aid identification of new phenotypes
and improve on assessments based on traditional visual based assessment alone.
4.2.3. Discovering Genotype-Phenotype Associations
Four large collaborative genomic and multi-omic programs and biobanks are estab-
lished for PAH—PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary
Vascular Disease Phenomics), US PAH Biobank, and UK national IPAH cohort [9,77–79].
Bone morphogenetic receptor type 2 (BMPR2) gene abnormalities are the most common
cause of heritable PAH, comprising ~15% of all cases, but 20+ new genes have been iden-
tified [9,80]. Patients with BMPR2 mutations are unlikely to demonstrate vasoreactivity,
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which informs clinical management [81]. Advances in genetic understanding and targeting
BMPR2 have developed novel therapies that are tested in clinical trials [82].
The distinct imaging appearances of these phenotypes are not currently well charac-
terized. Cardiac MRI has demonstrated right ventricular (RV) function to be more severely
affected in BMPR2 patients, but CT features are currently an area of research [83]. Marrying
genetic data with imaging data offers the potential for better phenotype patients.
4.3. Prognostication
4.3.1. Predicting Treatment Response and Survival
In idiopathic pulmonary fibrosis (IPF), texture based QCT of lung parenchymal disease
patterns was superior to both visual scoring and traditional lung function tests in predicting
outcomes [84]. QCT specific lung texture patterns were also found to be an independent
predictor for survival when comparing short term interval changes between two scans [85].
For radiologist interpretation, only the overall disease progression was a predictor, and
not specific lung features. Models have also demonstrated the ability to identify and select
patients who would be steroid responders [86]. In chronic hypersensitivity pneumonitis,
extent of fibrosis and reticulation independently predicted time to death or lung transplan-
tation [87]. Another study found severity of traction bronchiectasis and honeycombing to
predict mortality [88]. As an example of going beyond conventional metrics such as lung
function tests, severity of traction bronchiectasis on HRCT (High-resolution computed
tomography) was found to be an independent predictor for mortality in those patients that
had marginal annual forced vital capacity (FVC) declines [89].
In COPD, large longitudinal multicenter prospective trials such as COPDGene and
SPIROMICS include QCT data to better understand the disease process [90,91]. The results
of these studies have found the impact of QCT metrics on a vast range of outcomes [92,93].
In emphysema, lung volume reduction surgery is a treatment in which disease distribution
pattern and fissure integrity are important predictors of success [94]. Regional quantifica-
tion by QCT models here has shown to predict postoperative lung function, thereby aiding
clinical decision making [95]. These findings demonstrate the prognostic potential of QCT
in PH.
4.3.2. Imaging Biomarkers as Clinical Endpoints
Traditional biochemical biomarkers in PAH include B-type natriuretic peptide (BNP)
and N-terminal pro-brain natriuretic peptide, which non-specifically correlate with myocar-
dial function and pulmonary haemodynamics [96]. These are routinely used in practice to
inform clinical opinion.
Imaging biomarkers are imaging features of pathological conditions [97]. Traditional
CT imaging biomarkers in PH include mPA size and secondary signs of heart failure such
as inferior vena cava dilation, pleural effusions, and septal lines [27]. An mPA size >29 mm
has 97% positive predictive value for PH, and a PA to ascending aorta ratio >1 is 92%
specific for a raised mean arterial pressure >20 mmHg [29,98,99]. Quantitative CT enables
more complex biomarkers that can combine multiple measurements or perform higher
level textural analysis to create a model that could be then validated to be diagnostic or
prognostic value. While the majority of studies focus currently on the analytical perfor-
mance of such models, Swift et al. last year validated a CT model against clinical outcomes
to demonstrate both diagnostic and prognostic value in suspected PH [28].
Current assessment tools in PH clinics and endpoints used in clinical trials such as
the 6 minute walking distance and right heart catheterization are limited, in part, by their
insensitivity to change and their invasive nature, respectively [29]. As highlighted by the
Pulmonary Vascular Research Institute statement on imaging in PH, there is a need to
identify new tools for both clinical use and for use as endpoints in studies [29]. There
is particularly an unmet need for biomarkers that can help differentiate between PAH
and PH-Lung [17]. Imaging biomarkers identified by QCT metrics may help solve this
clinical dilemma.
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Repeatable and quantifiable imaging biomarkers can measure treatment response and
are currently being used as endpoints for clinical investigations and trials in emphysema
and ILD [29,100,101]. QCT metrics have been shown to predict outcomes better than lung
function tests in ILD [84,89].
4.3.3. Enabling Precision Medicine and Big Data Analysis
The numerical nature of QCT derived imaging biomarkers naturally integrates well
with big data analysis in precision medicine. Precision medicine is a process of enabling
targeted tailored therapies to patient groups through deep phenotyping of patients [102].
The goal is bringing together data from genetics, imaging, immunology/histology, and
traditional clinical assessment in a holistic manner to refine diagnosis and offer target
therapies that improve outcomes. PH as a heterogeneous condition with distinct sub-
phenotypes is well suited for precision medicine. A multi-domain and multimodality
approach is already established for clinical assessment. The tenth biannual symposium of
the International Society for Strategic Studies in Radiology recognized the implementation
of quantitative imaging as critical to this goal [103]. It highlighted how imaging findings
have strong yet currently untapped potential to guide patient care and influence outcome
through imaging-based biomarkers.
5. Limitations, Challenges, and Solutions
The promise and the potential of AI should be tempered by a realistic, pragmatic
understanding of current limitations. We highlight three limitations to chest QCT and
discuss three challenges faced by all ML, radiomic, and imaging biomarker studies.
5.1. Limitations in Quantitative CT Research
5.1.1. Variations in Data
A large number of steps exist within the imaging data pipeline, each of which can
add variation and noise to the data. These include CT image acquisition parameters,
reconstruction, segmentation, feature-extraction and post-processing algorithms. These
factors reduce the robustness, performance, and generalisability of radiomics or imaging
biomarker approaches, including quantitative CT.
Solutions are therefore an active area of research. The Image Biomarker Standardisa-
tion Initiative and groups such as the Quantitative Imaging Biomarker Alliance, and the
Association of University Radiologists Research Alliance Quantitative Imaging Task Force
are dedicated to such solutions [51,104,105]. These range from standardisation of imaging
protocol to more recent algorithms and data processing techniques that limit variance.
The SPIROMICS study developed an imaging protocol specifically for Chest QCT [91].
Pyradiomics is a flexible open-source approach to feature extraction, allowing for more
widespread reproducible feature analysis [106]. Differences in extracted features between
different CT scanners can be tested with physical phantoms to understand the underlying
variation [107]. These features can then be standardised amongst protocols to account
for this invariance [97,108]. Differences in slice thickness, voxel sizes and convolutional
kernels can be normalised using a range of approaches such as voxel-size resampling,
batch effect correlation, and grey-level normalisation [109–111]. A predictive internal
calibration approach was shown to improve performance of emphysema prediction in a
COPD study [112]. Moving to an ML based automated approach for segmentation has
higher accuracy and reduced variability compared to manual segmentation [113]. For
DL approaches, domain adaptation and transfer learning are approaches insensitive to
data heterogeneity [97,114,115]. Convolutional neural networks have been shown to dra-
matically improve the similarity of CT radiomic features obtained with different imaging
reconstruction algorithms and kernels [116].
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5.1.2. Inspiration, Breathing and Motion Artefacts
Differences in lung volume secondary to inspiratory effort and artefacts from breathing
and cardiac motion are inherent to chest CT [117]. They limit traditional visual asessment
for radiologists and can lead to misinterpretation, as pulmonary density is influenced by
respiratory phase. For a quantitative approach, these must be minimised to avoid errors
propagating throughout the pipeline. Failure to do so can lead to errors where the disease
is improperly quantified. Solutions include use of modern scanners with rapid acquisition
times and larger detectors, clear instructions to patients to explain the importance of breath
holding, and data techniques to adjust for variability. Parametric response mapping is a
method where volumetric non-rigid registration of both inspiratory and expiratory scans
are fused [118]. The overall lung volume can be quantified to alert for differences and used
to normalise or weight measurements [119].
5.1.3. Lack of Studies Involving Intravenous Contrast
Most QCT applications to date use non-contrast CT. In PH, most studies involve intra-
venous contrast and are performed as a CT Pulmonary Angiogram (CTPA). Intravenous
contrast increases the opacification of the lung parenchyma due to perfusion of a high
density contrast media throughout the pulmonary vessels and lung parenchyma. Whilst
the volume and speed of contrast material administered is routinely standardised, there
can be variability between scans in the extent of contrast uptake within lung parenchyma.
In pulmonary nodule characterization studies, this variability was reduced by acquiring
images between 60–150 sec post injection [97,120]. We found only one study assessing
lung parenchymal patterns in contrast Chest CT, finding significant difference in mean
lung density in patients with pulmonary embolism [121]. This is an area in need of further
research. Can the existing algorithms trained on non-contrast CT be applied to CTPA?
Can they be adapted using additional information such as density of contrast in main
pulmonary arteries and cardiac chambers?
5.2. Current Challenges Facing Machine Learning Research
5.2.1. High-Quality Training Data Is Hard to Obtain
Development of any algorithm requires robust training data—both in quantity and
quality. The performance of ML models improves logarithmically with increased volume of
training data available [122–124]. As the algorithm ‘learns’ through feature recognition, the
quality of the training cohort fundamentally shapes its performance. An ideal training data
set is contextual to the problem it seeks to address, expertly labelled, quality controlled
against imaging artefacts and noise, and appropriately powered for its clinical use. It
should follow the FAIR principles of scientific data management and stewardship—be
Findable, Accessible, Interoperate and Reusable [125]. The lack of high-quality labelled
training data is a limitation throughout all domains of ML research. Carefully preparing,
validating and labelling training data often form the bulk of the development work [124].
All patient identifiable information needs to be carefully removed from any imaging
data set prior to use. Although standards exist for medical imaging data such as DICOM,
they are only loosely adhered to, with wide variation in the metadata [124]. Patient
information can be difficult to remove, and at times hard coded into the imaging data.
Clinical governance standards are stricter for medical data, and mandate secure data
management and storage solutions.
To address these challenges, standardised and data validation systems have been
proposed. Kohli et al proposed an extensive 16 point baseline metadata list to consider to
catalog medical imaging data [126]. A Medical imaging DAta Readiness (MiDAR) scale has
been proposed as a four-point framework that assesses the readiness of medical imaging
data for development [124]. All AI studies should have a data preparation and quality
control framework that ensures training data robustness.
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5.2.2. Lack of External Multi Centre Validation and Prospective Studies
ML algorithms should be validated in external multi-centre cohorts to avoid overfit-
ting. Overfitting describes the ML model being exceedingly narrow in its performance,
such that it learns from noise and other specific quirks of the training data. Therefore, its
performance degrades on external validation cohorts when other variances and variables
are present. Overfitting is a major obstacle that hinders generalizability—the application
of the clinical model in other similar cohorts or centres. This can be minimised by us-
ing a large, diverse training dataset and performing techniques such as augmentation,
regularisation and dropout [127].
Of 82 studies describing 147 patient cohorts that compared AI performance vs health
care professionals, Liu et al found only 25 performed external validation [41]. Of these, only
14 used the same sample for comparison. Another review found only 9 to be prospective
and 6 to be tested in a real world clinical setting [128]. Both reviews found a high risk
of potential bias in the validation procedures and poor methodology in study design.
These findings highlight the need for further prospective studies designed with external
multi-centre validation as a primary target. The need for generalisability inherently has the
trade-off for poorer performance across those several centres over stronger performance at
a single centre [129]. The retrospective nature of studies leads to large variations in imaging
protocols, sample sizes and AI approaches. There is a need for standardisation in reporting
practices [130]. In late 2020, SPIRIT-AI (Standard Protocol Items: Recommendations for
Interventional Trials-Artificial Intelligence) and CONSORT-AI (Consolidated Standards of
Reporting Trials-Artificial Intelligence) standards were published to help improve this in
the context of interventions and clinical trials involving AI [131,132].
5.2.3. ‘Black Box’ and Interpretability
DL approaches by design have multiple hidden layers that obscure the decision-
making process. This lack of transparency has been labelled a ‘black box’ problem. Ap-
proaches are being developed that offer more insight to improve interpretation, such as
through visualisation of features [133]. Medical systems and workflows value interop-
erability as assumptions can be checked and errors appropriately evaluated. There are
debates from a legal, regulatory and accountability standpoint regarding the suitability of
such systems. Explainable and interpretable AI therefore is a field which is getting more
interest. [134]. In the near future, we expect QCT models to serve as an adjunct to visual
assessment. Therefore, AI and ML systems which are more clinically comprehensible and
better integrated into current clinical imaging workflows will be preferred.
6. Conclusions
Leveraging the power of ML has demonstrated significant breakthroughs in a range
of lung diseases. These can be applied to improve both radiological assessment and clinical
management in pulmonary hypertension. Quantitative imaging in particular can lead to a
data-driven decision-making process which combines clinical, physiological, genetic and
radiological data for better assessment. This would help answer the topical clinical and
radiological problems in the field—helping with better phenotyping and assessment for
treatment decisions. Once validated, imaging-based biomarkers can help assess treatment
response and therefore can be used as endpoints in clinical trials. The growing use of
AI will help reduce errors, increase productivity, and can enable a precision medicine
approach to pulmonary hypertension.
It is, however, important to be realistic and pragmatic about the current state of
medical imaging using AI, with a clear understanding of its limitations. AI has been
shown to excel in the narrow domain sensory image perception and identification tasks.
It however does not have the ability to make broader assessments away from its domain,
recognise the larger context of its use or even appraise if it is being deployed appropriately.
This role falls to humans. Current AI should best be viewed and used as a specific tool in a
validated narrow clinical context. Going forward, further prospective, large multi-centre
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studies are required to better assess technical development in clinical settings. Studies
using clinically meaningful endpoints for AI algorithms such as treatment response and
survival are preferred over purely technical performance in image classification.
In conclusion, for physicians managing patients with PH and associated lung disease,
it is hoped that the application of AI approaches to CT imaging, may “come to the rescue”
by providing mechanistic insights and improved phenotyping and by doing so facilitate
much needed therapy trials.
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